INVIVYD, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
INVIVYD, INC. (IVVD) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 37.83 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-13
- INVIVYD, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 36.43M shares, a 15.51% increase year-over-year.
- INVIVYD, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 31.54M shares, a 4.97% decline year-over-year.
- INVIVYD, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 33.19M shares, a 7.75% increase year-over-year.
- INVIVYD, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 30.80M shares, a 43.97% increase year-over-year.
- INVIVYD, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 29.72M shares, a 36.23% increase from fiscal 2024.
- INVIVYD, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 21.81M shares, a 27.03% decline from fiscal 2023.
- INVIVYD, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 29.89M shares, a 1.76% decline from fiscal 2022.
- INVIVYD, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 30.42M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 1 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 4 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 7 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 37.83M shares 10-Q · filed 2026-08-13 | ||||||
| 2026-03-31 | 36.43M shares 10-Q · filed 2026-05-14 | ||||||
| 2025-12-31 | 29.72M shares 10-K · filed 2026-03-05 | ||||||
| 2025-09-30 | 29.68M shares 10-Q · filed 2025-11-06 | ||||||
| 2025-06-30 | 29.74M shares 10-Q · filed 2026-08-13 | ||||||
| 2025-03-31 | 31.54M shares 10-Q · filed 2026-05-14 | ||||||
| 2024-12-31 | 21.81M shares 10-K · filed 2026-03-05 | ||||||
| 2024-09-30 | 28.70M shares 10-Q · filed 2025-11-06 | ||||||
| 2024-06-30 | 31.86M shares 10-Q · filed 2025-08-14 | ||||||
| 2024-03-31 | 33.19M shares 10-Q · filed 2025-05-15 | ||||||
| 2023-12-31 | 29.89M shares 10-K · filed 2025-03-20 | ||||||
| 2023-09-30 | 28.90M shares 10-Q · filed 2024-11-14 | ||||||
| 2023-06-30 | 28.68M shares 10-Q · filed 2024-08-14 | ||||||
| 2023-03-31 | 30.80M shares 10-Q · filed 2024-05-09 | ||||||
| 2022-12-31 | 30.42M shares 10-K · filed 2024-03-28 | ||||||
| 2022-09-30 | 21.82M shares 10-Q · filed 2022-11-10 | 21.82M shares 10-Q · filed 2023-11-09 | |||||
| 2022-06-30 | 20.42M shares 10-Q · filed 2022-08-15 | 20.42M shares 10-Q · filed 2023-08-10 | |||||
| 2022-03-31 | 21.40M shares 10-Q · filed 2023-05-11 | ||||||
| 2021-12-31 | 21.95M shares 8-K · filed 2024-02-09 | ||||||
| 2021-09-30 | 21.32M shares 10-Q · filed 2022-11-10 | 21.32M shares 10-Q · filed 2022-11-10 | |||||
| 2021-06-30 | 103.85M shares 10-Q · filed 2022-08-15 | 103.85M shares 10-Q · filed 2022-08-15 | |||||
| 2021-03-31 | 71.80M shares 10-Q · filed 2022-05-13 | ||||||
| 2020-12-31 | 71.80M shares 10-K · filed 2022-03-31 | ||||||
| 2020-09-30 | 66.10M shares 10-Q · filed 2021-11-15 | ||||||
| 2020-06-30 | 5.59M shares 10-Q · filed 2021-09-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |